Central Precocious Puberty (CPP)
5
Pipeline Programs
2
Companies
2
Clinical Trials
4
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
4
Early DiscoveryClinical DevelopmentMarket
On Market (4)
Approved therapies currently available
Competitive Landscape
2 companies ranked by most advanced pipeline stage
City TherapeuticsMA - Cambridge
1 programSpexin and Phoenixin-20 in Girls With Central Precocious PubertyN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AbbVieLeuprolide Acetate
City TherapeuticsSpexin and Phoenixin-20 in Girls With Central Precocious Puberty
Clinical Trials (2)
Total enrollment: 45 patients across 2 trials
A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)
Start: Oct 2018Est. completion: Nov 202345 patients
Phase 3Completed
Spexin and Phoenixin-20 in Girls With Central Precocious Puberty
Start: Dec 2024Est. completion: Jan 2026
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space